Green Griffith successfully asserted Horizon’s Orange-Book-listed U.S. Patent No. 9,066,913 covering its PENNSAID® 2% (topical diclofenac sodium) product in Hatch-Waxman litigation against generic challenger, Teva.
Horizon and Green Griffith Win Case v. Actavis Laboratories
